ORLANDO, Fla., July 19, 2016 /PRNewswire/ -- Profounda, Inc. ("Profounda") announced today that Rhinase® is now available in the United States immediately on Rhinase.com and Amazon.com.
Today, patients have limited options for controlling problematic nasal symptoms. Saline rinses use mechanical force to clear clogged noses but are not focused on moisturizing, while steroids may be needed to control symptoms of moderate-to-severe allergic rhinitis, yet overuse can be an issue. A 2010 nasal allergy survey revealed that nearly 64 percent of patients discontinue the use of nasal steroid prescriptions due to the unwanted side effects. Both saline rinses and steroids along with other decongestants may leave your nasal passages overly dry resulting in burning and stinging. This can leads to excess mucus created by your body as it tries to compensate for the lack of moisture. Only Rhinase is formulated with two salts and two wetting agents designed to work alone or with your other allergy products to provide the extra moisture needed for a dry nose.
"Wetting agents have been proven to help patients with nasal dryness since the 1980's" said Todd MacLaughlan, CEO of Profounda, "Rhinase will also complement the use of steroids because unlike many products, it has the same pH and therefore is less likely to interfere with the steroids effectiveness."
About Profounda, Inc.
Profounda is a product-oriented, privately backed pharmaceutical company that aims to license or develop high quality specialty niche pharmaceutical products in the branded, OTC and generic pharmaceutical markets. Our objective is to focus on bringing high quality innovative options to patients being treated for various conditions in order to improve the lives of those that take our medication. Profounda's first commercial OTC products, Rhinase® Soothing Nasal Gel and Rhinase® Lubricating Nasal Mist will help patients with nasal dryness associated with allergies. Impavido was Profounda's first Rx product launched in the U.S. by Profounda and the first and only oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the U.S. Food and Drug Administration ("FDA") and is also recommended by the CDC for the non-approved use of primary amebic meningoencephalitis (PAM). Profounda is also developing a potential first to file generic product competing in a $100+ million brand market. For more information, visit Profounda's website at www.profounda.com.
For further information, please contact:
SOURCE Profounda, Inc.